Sartorius became the supplier of ABL Europe

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems.

Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg. A subsidiary of ABL Inc., ABL Europe provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.

Sartorius Stedim Biotech has delivered a comprehensive GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration and mixing. These have been installed at the facility, which is now in the process of manufacturing batches of viral vector products for ABL’s clients. Sartorius Stedim Biotech’s end-to-end process solutions in single-use (SU) format have helped ABL expand its existing drug substance capacity, with a fully disposable manufacturing capability for different viral vector product types produced in non-adherent cell lines.

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.

SOURCE: sartorius
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.